Company
Gilead Sciences, Inc.
Headquarters: Foster City, CA, United States
Founded: June 22, 1987
Employees: 14,400
CEO: Mr. Daniel P. O'Day
Market Cap
$107.68 Billion
USD as of Jan. 1, 2023
Gilead Sciences, Inc. Categories
United States
languages
Healthcare
languages
Drug Manufacturers—General
United States Healthcare
United States Drug Manufacturers—General
Company Description
Gilead Sciences, Inc., is a pharmaceutical and biotechnology company focusing on antiviral drugs to treat HIV, hepatitis B, hepatitis C, and influenza, notably producing and commercializing the blockbuster drugs Harvoni and Sovald. Besides, Gilead conducts research to develop a pipeline of new drugs and treatments and it also considers the acquisition of other blockbuster drugs.
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
|
Pfizer
|
$287.63 B |
|
AbbVie
|
$285.80 B |
|
Merck
|
$281.30 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$495.37 B |
|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
Novo Nordisk
|
$304.61 B |
|
Pfizer
|
$287.63 B |
Detailed Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Stocks & Indices
Gilead Sciences, Inc. has the following listings and related stock indices.
Stock: NASDAQ: GILD
- show_chart NASDAQ Composite
- show_chart NASDAQ-100
- show_chart Russell 1000
- show_chart Russell 3000
- show_chart S&P 500
Stock: BCBA: GILD
Stock: BMV: GILD
Stock: Bovespa: GILD34
Stock: FSX: GIS
Stock: MTA: GILD
Product & Services
AmBisome Atripla Biktarvy Complera Cayston Descovy Emtriva Epclusa Genvoya Harvoni Hepsera Letairis Lexiscan Macugen Odefsey Ranexa Sovaldi Stribild Tamiflu Truvada Tybost Veklury Vemlidy Viread Vosevi Yescarta Zydelig
Key People
Daniel O' Day (CEO and Chairman) Andrew Dickinson (CFO) Tomáš Cihlář (Vice president, and Senior Director, Biology)
Financials
Revenue: US$22.45 billion (2019)
Operating income: US$4.29 billion (2019)
Net income: US$5.39 billion (2019)
Total assets: US$61.63 billion (2019)
Total equity: US$22.65 billion (2019)